



AVAILABLE TECHNOLOGY

"TECHNOLOGY SCROLL"

FOSTERING BIOTECH BUSINESS

VOLUME III

PHARMACEUTICAL AND HEALTHCARE

PO.BHAT-382 428

**GUJARAT STATE BIOTECHNOLOGY MISSION** 

C1914 EDILL LIBRARY AHMEDABAD

### **DISCLAIMER**

The technology scroll is a compilation and reproduction of information available on public domains. GSBTM does not take responsibility of the contents or its validation. While every effort has been made to ensure that the information contained in this document is accurate at the time of going to press, no liability for damage is accepted by GSBTM arising from any errors or omissions that may appear, in the final form.

GSBTM has reproduced the information, contents, as they have been placed by the respective organization on their websites. However classification has been done so as to make it more client and user friendly.

All rights of publication of this product in this form, design, layout, are reserved by GSBTM. No part of this publication in this form, design, layout, may be reproduced, or transmitted, by any means, mechanical, photocopying, recording or otherwise, without the permission of GSBTM.


#### About this Compilation


Technology Scroll, is an initiative of Gujarat State Biotechnology Mission, under aegis of Government of Gujarat. The compilation has been done by GSBTM team. For more information on the matters / technologies, please refer to the contact details provided.

#### Editorial Note

To request more information on GSBTM or Gujarat Biotechnology sector, or to order copies of whole compilation(s), please contact:: Mission Director Gujarat State Biotechnology Mission Department of Science & Technology, Government of Gujarat Block-11, 9th Floor, Udyog Bhavan, Gandhinagar 382 011 Tel: +91 79 232 52196, 97 Fax: +91 79 232 52195 mdbtm@gujarat.gov.in/

Copyright © 2006 GUJARAT STATE BIOTECHNOLOGY MISSION







#### Narendra Modi CHIEF MINISTER GUJARAT STATE





Sardar Bhavan, Sachivalaya, Block No. 1, 5th Floor, Gandhinagar-382 010. Gujarat Phone: (O) (079) 23232611 to

23232619

Fax No.: (079) 2322210

#### Message of H' ble Chief Minster of Gujarat

#### Technology scroll

Relevance of science & technology lies in its ability to contribute to socio-economic welfare of human society. The state of Gujarat is aware and abreast of the expanding vistas of modern technologies and its potential to facilitate socio-economic development and therefore, state has identified Biotechnology, as Growth Engine for future progress. Gujarat has firm belief that Biotechnology will not only fuel the development of diverse sectors and related industries but has proven potential for wealth creation as well.

Conversion of technological innovations into business enterprise and wealth creation, thereby, is the need, reflection and measure of a knowledge based economy. Business translation in knowledge economy is a function of opportunities created by new technologies and the entrepreneurship skills. The globally demonstrated entrepreneurship spirit of Gujarat has always been there to explore the new areas of business including those emanating from sunrise technologies such as Biotechnology.

In this regard, the **Technology Scroll**, brought out by Gujarat State Biotechnology Mission,, is a logical, timely and right step forward. This scroll would encourage and facilitate entrepreneurs to venture into the business arena of this emerging science. It is hoped that it would be instrumental in stimulating biotechnology based entrepreneurship in Gujarat.

I am sure that the purpose and spirit with which Technology scroll has been prepared, shall be realized to the fullest and for the benefit of all. I extend my heartiest congratulations and Best wishes, to Gujarat state Biotechnology mission, for their laudable efforts in developing this exclusive compilation.

(Narendra Modi)



CHIEF SECRETARY

GOVERNMENT OF GUJARAT

Gujarat is among the most industrialized States in the country. The State has achieved impressive growth in chemical, manufacturing, mining and textile sectors. The State is now moving towards rapid development of knowledge industries, focusing on information and bio-technologies. The State Biotechnology Mission has prepared a Technology Scroll which lists technologies globally available for business entrepreneurs. The scroll illustrates opportunities for investment in the bio-technology application and would be of immense help to entrepreneurs in identifying potential for investment. This is a commendable effort of the Gujarat State Biotechnology Mission and I hope that the compilation would be found useful by bio-technology entrepreneurs.

(S.G. Mankad)



## Message of Secretary, Science & technology

## Technology Scroll

Biotechnology, undoubtedly, is the growth engine of the future. With its cutting edge technology innovation and vast applications in multiple sector it stands to offer cost effective solutions to society. Knowledge harnessing for socio-economic development is a function of research and entrepreneurship. While application based research is the need of hour, availing the opportunities through developed work is equally significant and logically desirable.

This inventory of potential business opportunities in Biotechnology sector would not only facilitate start ups, new entrepreneurs and existing players but shall also encourage higher level of business activity in Biotechnology in the state. The technology scroll shall enable increased interaction among the stakeholders and facilitate business relationship. The benefits of this compilation to industry, commerce, academia or researchers are alike.

I convey my sincere wishes and heartiest congratulations to Gujarat State Biotechnology Mission for coming up with this novel idea and trust that all would find this endeavor as initiative for catalyzing Biotechnology entrepreneurship in the State.

Raj Kumar

Tel: (Office) +91 - 79-232 50321, 232 59999

E-mail: secdst@gujarat.gov.in

+91 - 79-232 50325

## **Foreword**

On behalf of Gujarat State Biotechnology Mission, Department of Science & technology, I am delighted to bring to you the first version of Technology Scroll

Having identified, Biotechnology, as Growth engine for next few decades and also as singular most potential tool for socio-economic development-- Government of Gujarat,, is committed to facilitate the process of transformation of traditional economy and catalyze the growth of Biotechnology in the state. As world wide trends underline, the role of Biotechnology, in the convergence of several old economy industries- Gujarat, with its strong background of traditional industries -- looks towards this emerging science with hope and vision.

The initiative of preparation of Technology Scroll is in line with, the strategy of Government of Gujarat, to move towards economy which is driven by modern technologies. The objectives of this compilation is to

Facilitate the convergence of traditional industries of Gujarat, towards use and adoption of Biotechnology,
Encourage the knowledge and innovation based entrepreneurship in the state,
Enable the techno-economic benefits of newly available technologies,
Facilitate global networking of knowledge and technologies for business translation,
Encouraging Biotechnology business,

Gujarat has traditional strengths in Pharmaceuticals, chemicals, agriculture, animal husbandry, food processing sectors. The inherent strength of infrastructure, natural resource, intellectual capital and financially stable economy, provide ideal foundation for leveraging these strengths -- to converge towards and diversify-- into niche biotechnology segments.

While Global entrepreneurs have been major value wealth creators in Biotechnology business, it is the wide base of techno-based entrepreneurship, which stands to provide, the critically needed impetus. Globally proven entrepreneurship spirit of Gujarat, needs the opportunities with business potentials. And Technology Scroll prepared, just aims to do that.

It is compilation of Technology Database of approximately 600 Technologies developed and available globally. While 520 technologies are from different countries, mostly USA and Europe, around 80 technologies are the ones developed by research and academic institutes in India. The compilation covers a total of 9 Biotechnology Sectors, namely, agriculture, environment, Pharmaceuticals and healthcare, Animal Biotechnology; Bioinformatics; Food Biotechnology; Molecular Biotechnology; Nano Biotechnology Industrial Biotechnology To facilitate the stakeholders, Technology scroll has been brought out in sector specific volumes. To cater to the need and business interest of wide spectrum of product and process—encompassed by these 9 sectors of biotechnology—the compilation covers, around 170 Sub-sectors. 78 technologies from Agriculture & allied areas, 71 technologies from Industrial biotechnology, 197 technologies from Pharmaceutical & healthcare, 103 technologies from Animal Biotechnology; Bioinformatics; Food Biotechnology; Molecular Biotechnology; Nano Biotechnology and 41 technologies from environment biotechnology, provide the rich substratum for future business venture and entrepreneurship.

Preparation of technology Scroll has its genesis in GSBTM, commitment to come up with products and outputs that facilitate Biotechnology foresight, entrepreneurship, business, investment and wealth creation.

As we aim to step into knowledge and technology driven era, I encourage and invite the Gujarati and other entrepreneurs alike to explore the business horizons of Biotechnology and second our efforts in elevating Gujarat to global Bio-Map.

I am sure that in the maiden effort of this nature, some lacunae are bound to creep in, which provide the scope for further improvement. It will be our constant endeavor to update the content of this compilation at regular interval. I invite and welcome your inputs and feedback.

Shri Akshay K Saxena, IFS Mission Director

The second secon	THE RESERVE OF THE PERSON NAMED IN COLUMN TWO IS NOT THE PERSON NAMED IN COLUMN TWO IS NOT THE PERSON NAMED IN
Volume - 1 Agriculture and Allied Areas	With an article of the control of the
Sub Sector	Pages
1.1 Agri-Diagnostics	1-8
1.2 Bio-control	9-28
1.3 Biodiversity Conservation	29
1.4 Bio-Fertilizers	30-38
1.5 Bio-Fuels	39-40
1.6 Bio-Prospecting	41
1.7 Field Crop	42
1.8 Genetic Engineering	43-44
1.9 Genomics/Proteomics	45-47
1.10 GM Crop	48-51
1.11 Horticulture	52-55
1.12 Industrial Products	56
1.13 Instrumentation	57
1.14 Medicinal aromatic Plants	58
1.15 Plant Breeding	59-63
1.16 Plant Molecular Biology	64-71
1.17 Plantibodies	72
1.18 Preservation	73
1.19 Tissue Culture	74-77
1.20 Transgenic	78-80
1.21 Waste Management	81-83
1.21 Waste Management	01-03
Volume – 2 INDUSTRIAL BIOTECHNOLOGY	
Sub Sector	THE RESERVE THE PERSON NAMED IN COLUMN TWO IS NOT THE PERSON NAMED IN COLUMN TWO IS NAMED IN COLUMN TWO I
	Pages
	Pages 1
2.1 Anti-microbial Targets	1
2.1 Anti-microbial Targets 2.2 Biodegradation	1 2-3
<ul><li>2.1 Anti-microbial Targets</li><li>2.2 Biodegradation</li><li>2.3 Biofuels</li></ul>	1 2-3 4-5
2.1 Anti-microbial Targets 2.2 Biodegradation 2.3 Biofuels 2.4 Bio-Process	1 2-3
<ul> <li>2.1 Anti-microbial Targets</li> <li>2.2 Biodegradation</li> <li>2.3 Biofuels</li> <li>2.4 Bio-Process</li> <li>2.5 Genetic Diversity Exploitation &amp;</li> </ul>	1 2-3 4-5 6-23
<ul> <li>2.1 Anti-microbial Targets</li> <li>2.2 Biodegradation</li> <li>2.3 Biofuels</li> <li>2.4 Bio-Process</li> <li>2.5 Genetic Diversity Exploitation &amp; Therapeutics</li> </ul>	1 2-3 4-5 6-23
<ul> <li>2.1 Anti-microbial Targets</li> <li>2.2 Biodegradation</li> <li>2.3 Biofuels</li> <li>2.4 Bio-Process</li> <li>2.5 Genetic Diversity Exploitation &amp; Therapeutics</li> <li>2.6 Immobilization</li> </ul>	1 2-3 4-5 6-23 24 25
<ul> <li>2.1 Anti-microbial Targets</li> <li>2.2 Biodegradation</li> <li>2.3 Biofuels</li> <li>2.4 Bio-Process</li> <li>2.5 Genetic Diversity Exploitation &amp; Therapeutics</li> <li>2.6 Immobilization</li> <li>2.7 Industrial Products</li> </ul>	1 2-3 4-5 6-23 24 25 26-58
<ul> <li>2.1 Anti-microbial Targets</li> <li>2.2 Biodegradation</li> <li>2.3 Biofuels</li> <li>2.4 Bio-Process</li> <li>2.5 Genetic Diversity Exploitation &amp; Therapeutics</li> <li>2.6 Immobilization</li> <li>2.7 Industrial Products</li> <li>2.8 MABs</li> </ul>	1 2-3 4-5 6-23 24 25 26-58 59
<ul> <li>2.1 Anti-microbial Targets</li> <li>2.2 Biodegradation</li> <li>2.3 Biofuels</li> <li>2.4 Bio-Process</li> <li>2.5 Genetic Diversity Exploitation &amp; Therapeutics</li> <li>2.6 Immobilization</li> <li>2.7 Industrial Products</li> <li>2.8 MABs</li> <li>2.9 Microbiology</li> </ul>	1 2-3 4-5 6-23 24 25 26-58 59 60
2.1 Anti-microbial Targets 2.2 Biodegradation 2.3 Biofuels 2.4 Bio-Process 2.5 Genetic Diversity Exploitation & Therapeutics 2.6 Immobilization 2.7 Industrial Products 2.8 MABs 2.9 Microbiology 2.10 Microbiology/Strain Improvement	1 2-3 4-5 6-23 24 25 26-58 59
2.1 Anti-microbial Targets 2.2 Biodegradation 2.3 Biofuels 2.4 Bio-Process 2.5 Genetic Diversity Exploitation & Therapeutics 2.6 Immobilization 2.7 Industrial Products 2.8 MABs 2.9 Microbiology 2.10 Microbiology/Strain Improvement 2.11 Microbiology/Strain Improvement &	1 2-3 4-5 6-23 24 25 26-58 59 60 61-69
<ul> <li>2.1 Anti-microbial Targets</li> <li>2.2 Biodegradation</li> <li>2.3 Biofuels</li> <li>2.4 Bio-Process</li> <li>2.5 Genetic Diversity Exploitation &amp; Therapeutics</li> <li>2.6 Immobilization</li> <li>2.7 Industrial Products</li> <li>2.8 MABs</li> <li>2.9 Microbiology</li> <li>2.10 Microbiology/Strain Improvement</li> <li>2.11 Microbiology/Strain Improvement &amp; Therapeutics</li> </ul>	1 2-3 4-5 6-23 24 25 26-58 59 60 61-69
<ul> <li>2.1 Anti-microbial Targets</li> <li>2.2 Biodegradation</li> <li>2.3 Biofuels</li> <li>2.4 Bio-Process</li> <li>2.5 Genetic Diversity Exploitation &amp; Therapeutics</li> <li>2.6 Immobilization</li> <li>2.7 Industrial Products</li> <li>2.8 MABs</li> <li>2.9 Microbiology</li> <li>2.10 Microbiology/Strain Improvement</li> <li>2.11 Microbiology/Strain Improvement &amp; Therapeutics</li> <li>2.12 Therapeutics</li> </ul>	1 2-3 4-5 6-23 24 25 26-58 59 60 61-69
<ul> <li>2.1 Anti-microbial Targets</li> <li>2.2 Biodegradation</li> <li>2.3 Biofuels</li> <li>2.4 Bio-Process</li> <li>2.5 Genetic Diversity Exploitation &amp; Therapeutics</li> <li>2.6 Immobilization</li> <li>2.7 Industrial Products</li> <li>2.8 MABs</li> <li>2.9 Microbiology</li> <li>2.10 Microbiology/Strain Improvement</li> <li>2.11 Microbiology/Strain Improvement &amp; Therapeutics</li> </ul>	1 2-3 4-5 6-23 24 25 26-58 59 60 61-69
<ul> <li>2.1 Anti-microbial Targets</li> <li>2.2 Biodegradation</li> <li>2.3 Biofuels</li> <li>2.4 Bio-Process</li> <li>2.5 Genetic Diversity Exploitation &amp; Therapeutics</li> <li>2.6 Immobilization</li> <li>2.7 Industrial Products</li> <li>2.8 MABs</li> <li>2.9 Microbiology</li> <li>2.10 Microbiology/Strain Improvement</li> <li>2.11 Microbiology/Strain Improvement &amp; Therapeutics</li> <li>2.12 Therapeutics</li> <li>2.13 Therapeutics &amp; Vaccines</li> </ul>	1 2-3 4-5 6-23 24 25 26-58 59 60 61-69
2.1 Anti-microbial Targets 2.2 Biodegradation 2.3 Biofuels 2.4 Bio-Process 2.5 Genetic Diversity Exploitation & Therapeutics 2.6 Immobilization 2.7 Industrial Products 2.8 MABs 2.9 Microbiology 2.10 Microbiology/Strain Improvement 2.11 Microbiology/Strain Improvement & Therapeutics 2.12 Therapeutics 2.13 Therapeutics & Vaccines  Volume - 3 PHARMACEUTICALS & HEALTH CARE	1 2-3 4-5 6-23 24 25 26-58 59 60 61-69 70 71 72
2.1 Anti-microbial Targets 2.2 Biodegradation 2.3 Biofuels 2.4 Bio-Process 2.5 Genetic Diversity Exploitation & Therapeutics 2.6 Immobilization 2.7 Industrial Products 2.8 MABs 2.9 Microbiology 2.10 Microbiology/Strain Improvement 2.11 Microbiology/Strain Improvement & Therapeutics 2.12 Therapeutics 2.13 Therapeutics & Vaccines  Volume - 3 PHARMACEUTICALS & HEALTH CARE Sub Sector	1 2-3 4-5 6-23 24 25 26-58 59 60 61-69 70 71 72
2.1 Anti-microbial Targets 2.2 Biodegradation 2.3 Biofuels 2.4 Bio-Process 2.5 Genetic Diversity Exploitation & Therapeutics 2.6 Immobilization 2.7 Industrial Products 2.8 MABs 2.9 Microbiology 2.10 Microbiology/Strain Improvement 2.11 Microbiology/Strain Improvement & Therapeutics 2.12 Therapeutics 2.13 Therapeutics & Vaccines  Volume - 3 PHARMACEUTICALS & HEALTH CARE Sub Sector 3.1 Basic Research	1 2-3 4-5 6-23 24 25 26-58 59 60 61-69 70 71 72
<ul> <li>2.1 Anti-microbial Targets</li> <li>2.2 Biodegradation</li> <li>2.3 Biofuels</li> <li>2.4 Bio-Process</li> <li>2.5 Genetic Diversity Exploitation &amp; Therapeutics</li> <li>2.6 Immobilization</li> <li>2.7 Industrial Products</li> <li>2.8 MABs</li> <li>2.9 Microbiology</li> <li>2.10 Microbiology/Strain Improvement</li> <li>2.11 Microbiology/Strain Improvement &amp; Therapeutics</li> <li>2.12 Therapeutics</li> <li>2.13 Therapeutics &amp; Vaccines</li> <li>Volume - 3 PHARMACEUTICALS &amp; HEALTH CARE Sub Sector</li> <li>3.1 Basic Research</li> <li>3.2 Bio-Active Compounds</li> </ul>	1 2-3 4-5 6-23 24 25 26-58 59 60 61-69 70 71 72 Pages 1-3 4-7
2.1 Anti-microbial Targets 2.2 Biodegradation 2.3 Biofuels 2.4 Bio-Process 2.5 Genetic Diversity Exploitation & Therapeutics 2.6 Immobilization 2.7 Industrial Products 2.8 MABs 2.9 Microbiology 2.10 Microbiology/Strain Improvement 2.11 Microbiology/Strain Improvement & Therapeutics 2.12 Therapeutics 2.13 Therapeutics 2.13 Therapeutics & Vaccines  Volume - 3 PHARMACEUTICALS & HEALTH CARE Sub Sector 3.1 Basic Research 3.2 Bio-Active Compounds 3.3 Bio-Analytical Instrumentation	1 2-3 4-5 6-23 24 25 26-58 59 60 61-69 70 71 72 Pages 1-3 4-7 8
2.1 Anti-microbial Targets 2.2 Biodegradation 2.3 Biofuels 2.4 Bio-Process 2.5 Genetic Diversity Exploitation & Therapeutics 2.6 Immobilization 2.7 Industrial Products 2.8 MABs 2.9 Microbiology 2.10 Microbiology/Strain Improvement 2.11 Microbiology/Strain Improvement & Therapeutics 2.12 Therapeutics 2.13 Therapeutics 2.13 Therapeutics & Vaccines  Volume - 3 PHARMACEUTICALS & HEALTH CARE Sub Sector 3.1 Basic Research 3.2 Bio-Active Compounds 3.3 Bio-Analytical Instrumentation 3.4 Bio-Analytical Techniques	1 2-3 4-5 6-23 24 25 26-58 59 60 61-69 70 71 72 Pages 1-3 4-7 8 9-10
2.1 Anti-microbial Targets 2.2 Biodegradation 2.3 Biofuels 2.4 Bio-Process 2.5 Genetic Diversity Exploitation & Therapeutics 2.6 Immobilization 2.7 Industrial Products 2.8 MABs 2.9 Microbiology 2.10 Microbiology/Strain Improvement 2.11 Microbiology/Strain Improvement & Therapeutics 2.12 Therapeutics 2.13 Therapeutics 2.13 Therapeutics & Vaccines  Volume - 3 PHARMACEUTICALS & HEALTH CARE Sub Sector 3.1 Basic Research 3.2 Bio-Active Compounds 3.3 Bio-Analytical Instrumentation	1 2-3 4-5 6-23 24 25 26-58 59 60 61-69 70 71 72 Pages 1-3 4-7 8

Volume – 3 PHARMACEUTICALS & HEALTH CARE	5. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.
3.7 Bio-Medical Instrumentation	14-33
3.8 Bio-Medical Instrumentation / Molecular Diagnostics	34-35
3.9 Cell line Study	36
3.10 Cell line Study / Screening & Therapeutics	37
3.11 Clinical Trials	38
3.12 Clinical Trials & Therapeutics	39
3.13 Clinical Trials Management	40-44
3.14 Clinical Trials Management & Drug Delivery System	45
3.15 Compound Synthesis & Screening	46
3.16 CytoToxicity	47
3.17 Diagnostics & Therapeutics	48
3.18 Diagnostics	49-89
3.19 Diagnostics & Monitoring	90
3.20 Diagnostics & Predictives	91
3.21 Diagnostics & Therapeutics	92-109
3.22 Diagnostics & Treatment	110
3.23 Diagnostics & Vaccines	111-112
3.24 Diagnostics / MABs	113
3.25 Diagnostics, Therapeutics & Immunology	114-115
3.26 Diagnostics / Bioassays	116
3.27 Diagnostics / Instrumentation	117-120
3.27 Diagnostics / instrumentation	117 120
3.28 Drug Discovery	121-124
3.29 Functional Genomics	125
3.30 Gene Amplification	126
3.31 Gene Expression Study	127
3.32 Gene Therapy	128
3.33 Gene transfer & Therapeutics	129-130
3.34 Genetic diversity Exploitation	131
3.35 Genome Analysis	132
3.36 Genomics	133
3.37 Immuno Therapeutics	134-136
3.38 MABs	137-138
3.39 Media	139
3.40 Molecular Biology	140-141
3.41 Molecular Biomarkers & Therapeutics	142
3.42 Molecular Diagnostics	143-146
3.43 Molecular Diagnostics & Therapeutics	147-150
3.13 Molecular Plagnostics & Metapeatics	117 150
3.44 Molecular Diagnostics & Vaccines	151
3.45 Molecular Markers	152-153
3.46 Molecular Targets & Diagnostics	154-155
3.47 Molecular Therapeutics	156-162
3.48 Patient Management System	163
3.49 Pharmaco-genetics / Therapeutics	164
3.50 Pre-clinical Testing	165
3.51 Target Therapeutics	166
3.52 Targeted Molecular Therapeutics	167
3.53 Therapeutic Markers / MABs	168-169
3.54 Therapeutics	170-215
3.56 Therapeutics & Vaccines	217-219
3.57 Therapeutics / Drug Development	220
3.58 Tissue Engineering	221-227
3.59 Vaccines	228-231
3.55 Theraneutics & Targets	216

06-68	4.42 Gene Analysis & Diagnostics
88	4.41 Functional Biomolecule
<b>Z8</b>	4.40 Drug Discovery
98	4.39 Cloning
82	4.38 Biosensor
1/8	4.37 Biomaterials, Reagents
85-83	4.36 Bio-analytical Technique
18	4.35 Bio-analytical Instrumentation
08	4.34 Analytical Reagents
Pages	Sub Sector
	Sector - MOLECULAR BIOLOGY
0/.0/	4.32 Quality-Control
72-78 72-17	4.31 Preservatives
02-12	4.30 In-vitro Testing
69	4.29 Industrial Products
89-49	4.28 Genome Mapping
99-29	4.27 Food Safety
79-19	4.26 Food Quality
09-89	4.25 Food Products
ZS	4.24 Food Processing / Packaging / Preservation
99-09	4.23 Food Processing
67	4.22 Food Processes & Preservation
84-74	4.21 Food Borne Disease
97-57	4.20 Food Additives
39-44	4.19 Diagnostics
38	4.18 Bio-control / Bio-safety
Pages	Sub Sector
	Sector - FOOD BIOTECHNOLOGY
	ALTA SOLUMBIA DEVELOPINATE
37	4.16 Databases 4.17 Software Development
35-39 56-31	4.15 Computer Applications for Genomics
58	4.14 Bio-computing
76-27	4.13 Algorithms / Software Development
Pages	Sub Sector
	Sector - BIOINFORMATICS
1 1 t t	The state of the s
73-72	4.12 Vaccines
19-22	4.11 Therapeutics / Vaccines
18	4.10 Therapeutics
17	4.9 Recombinant Technology Diagnostics & Therapeutics
91	4.7 Immunobiology / Parasitology 4.8 MABs / Diagnostics
14-12	
11-13	
10	4.4 Diagnostics & Vaccines 4.5 Food Borne Diseases
6-8 Z-9	4.3 Diagnostics  A.B. Diagnostics & Vaccines
2-9	4.2 Dairy Products
I-2	4.1 Biomaterials
Pages	Sub Sector
Dane	Sector - ANIMAL BIOTECHNOLOGY
STEEL BOOK OF THE PERSON OF TH	Volume - 4

Volume – 3 PHARMACEUTICALS & HEALTH CARE	
3.7 Bio-Medical Instrumentation	14-33
3.8 Bio-Medical Instrumentation / Molecular Diagnostics	34-35
3.9 Cell line Study	36
3.10 Cell line Study / Screening & Therapeutics	37
3.11 Clinical Trials	38
3.12 Clinical Trials & Therapeutics	39
3.13 Clinical Trials Management	40-44
3.14 Clinical Trials Management & Drug Delivery System	45
3.15 Compound Synthesis & Screening	46
3.16 CytoToxicity	47
3.17 Diagnostics & Therapeutics	48
3.18 Diagnostics	49-89
3.19 Diagnostics & Monitoring	90
3.20 Diagnostics & Predictives	91
3.21 Diagnostics & Therapeutics	92-109
3.22 Diagnostics & Treatment	110
3.23 Diagnostics & Vaccines	111-112
3.24 Diagnostics / MABs	113
3.25 Diagnostics, Therapeutics & Immunology	114-115
3.26 Diagnostics / Bioassays	116
3.27 Diagnostics / Instrumentation	117-120
3.28 Drug Discovery	121-124
3.29 Functional Genomics	125
3.30 Gene Amplification	126
3.31 Gene Expression Study	127
3.32 Gene Therapy	128
3.33 Gene transfer & Therapeutics	129-130
3.34 Genetic diversity Exploitation	131
3.35 Genome Analysis	132
3.36 Genomics	133
3.37 Immuno Therapeutics	134-136
3.38 MABs	137-138
3.39 Media	139
3.40 Molecular Biology	140-141
3.41 Molecular Biomarkers & Therapeutics	142
3.42 Molecular Diagnostics	143-146
3.43 Molecular Diagnostics & Therapeutics	147-150
3.44 Molecular Diagnostics & Vaccines	151
3.45 Molecular Markers	152-153
3.46 Molecular Targets & Diagnostics	154-155
3.47 Molecular Therapeutics	156-162
3.48 Patient Management System	163
3.49 Pharmaco-genetics / Therapeutics	164
3.50 Pre-clinical Testing	165
3.51 Target Therapeutics	166
3.52 Targeted Molecular Therapeutics	167
3.53 Therapeutic Markers / MABs	168-169
3.54 Therapeutics	170-215
3.56 Therapeutics & Vaccines	217-219
3.57 Therapeutics / Drug Development	220
3.58 Tissue Engineering	221-227
3.59 Vaccines	228-231
3.55 Therapeutics & Targets	216

Volume – 4	
Sector - ANIMAL BIOTECHNOLOGY	
Sub Sector	Pages
4.1 Biomaterials	1-2
4.2 Dairy Products	3-5
4.3 Diagnostics	6-7
4.4 Diagnostics & Vaccines	8-9
4.5 Food Borne Diseases	10
4.6 Genetic Engineering	11-13
4.7 Immunobiology / Parasitology	14-15
4.8 MABs / Diagnostics	16
4.9 Recombinant Technology Diagnostics & Therapeutics	17
4.10 Therapeutics	18
4.11 Therapeutics / Vaccines	19-22
4.12 Vaccines	23-25
Sector - BIOINFORMATICS	
Sub Sector	Pages
4.13 Algorithms / Software Development	26-27
4.14 Bio-computing	28
4.15 Computer Applications for Genomics	29-31
4.16 Databases	32-36
4.17 Software Development	37
Sector - FOOD BIOTECHNOLOGY	
Sub Sector	Pages
4.18 Bio-control / Bio-safety	38
4.19 Diagnostics	39-44
4.20 Food Additives	45-46
4.21 Food Borne Disease	47-48
4.22 Food Processes & Preservation	49
4.23 Food Processing	50-56
4.24 Food Processing / Packaging / Preservation	57
4.25 Food Products	58-60
	61-62
	63-66
	67-68
4.29 Industrial Products	69
4.30 In-vitro Testing	70
4.31 Preservatives	71-74
4.32 Quality-Control	75-78
Sector - MOLECULAR BIOLOGY	
	Pages
4.30 In-vitro Testing 4.31 Preservatives	63-66 67-68 69 70 71-74

4.43 Gene Library	91-92
4.44 Gene Mapping	93
4.45 Gene Sequencing	94
4.46 Gene Therapy	95-97
4.47 Genetic Engineering	98-99
4.48 Genome Mapping	100-101
4.49 Genomics / Proteomics	102
4.50 Mapping & Cloning	103
4.51 Molecular Biology	104
4.52 Molecular Therapeutics	105
4.53 Therapeutics	106-107
4.54 Therapeutics & Vaccines	108
4.55 Transgenic Plant	109
Sector - NANO BIOTECHNOLOGY	
Sub Sector	Pages
4.56 Biomaterials	110
4.57 Biosensor	111
4.58 Biosensor & Diagnostics	112
4.59 Diagnostics	113-114
4.60 Functional Biomolecules	115
Volume – 5	
Sector - ENVIRONMENTAL BIOTECHNOLOGY	
Sub Sector	Pages
5.1 Bio-control	1-2
5.2 Bio-Process	1-2 3
	1-2
5.2 Bio-Process	1-2 3
5.2 Bio-Process 5.3 Bio-Remediation	1-2 3 4-16
<ul><li>5.2 Bio-Process</li><li>5.3 Bio-Remediation</li><li>5.4 Bio-Sensor</li><li>5.5 Genetic Engineering</li></ul>	1-2 3 4-16 17-21
5.2 Bio-Process 5.3 Bio-Remediation 5.4 Bio-Sensor 5.5 Genetic Engineering 5.6 Microbial Diversity	1-2 3 4-16 17-21 22-24
5.2 Bio-Process 5.3 Bio-Remediation 5.4 Bio-Sensor 5.5 Genetic Engineering 5.6 Microbial Diversity 5.7 Microbiology / Diagnostics	1-2 3 4-16 17-21 22-24 25-28
5.2 Bio-Process 5.3 Bio-Remediation 5.4 Bio-Sensor 5.5 Genetic Engineering 5.6 Microbial Diversity 5.7 Microbiology / Diagnostics 5.8 Pollution Management	1-2 3 4-16 17-21 22-24 25-28 29 30-47
5.2 Bio-Process 5.3 Bio-Remediation 5.4 Bio-Sensor 5.5 Genetic Engineering 5.6 Microbial Diversity 5.7 Microbiology / Diagnostics 5.8 Pollution Management 5.9 Sterilization Process	1-2 3 4-16 17-21 22-24 25-28 29 30-47 48
5.2 Bio-Process 5.3 Bio-Remediation 5.4 Bio-Sensor 5.5 Genetic Engineering 5.6 Microbial Diversity 5.7 Microbiology / Diagnostics 5.8 Pollution Management 5.9 Sterilization Process 5.10 Waste Management	1-2 3 4-16 17-21 22-24 25-28 29 30-47 48 49-53
5.2 Bio-Process 5.3 Bio-Remediation 5.4 Bio-Sensor 5.5 Genetic Engineering 5.6 Microbial Diversity 5.7 Microbiology / Diagnostics 5.8 Pollution Management 5.9 Sterilization Process 5.10 Waste Management 5.11 Waste Water Treatment	1-2 3 4-16 17-21 22-24 25-28 29 30-47 48 49-53
5.2 Bio-Process 5.3 Bio-Remediation 5.4 Bio-Sensor 5.5 Genetic Engineering 5.6 Microbial Diversity 5.7 Microbiology / Diagnostics 5.8 Pollution Management 5.9 Sterilization Process 5.10 Waste Management	1-2 3 4-16 17-21 22-24 25-28 29 30-47 48 49-53
5.2 Bio-Process 5.3 Bio-Remediation 5.4 Bio-Sensor 5.5 Genetic Engineering 5.6 Microbial Diversity 5.7 Microbiology / Diagnostics 5.8 Pollution Management 5.9 Sterilization Process 5.10 Waste Management 5.11 Waste Water Treatment 5.12 Bioremediation	1-2 3 4-16 17-21 22-24 25-28 29 30-47 48 49-53 54
5.2 Bio-Process 5.3 Bio-Remediation 5.4 Bio-Sensor 5.5 Genetic Engineering 5.6 Microbial Diversity 5.7 Microbiology / Diagnostics 5.8 Pollution Management 5.9 Sterilization Process 5.10 Waste Management 5.11 Waste Water Treatment 5.12 Bioremediation  Sector - MARINE BIOTECHNOLOGY	1-2 3 4-16 17-21 22-24 25-28 29 30-47 48 49-53 54 55
5.2 Bio-Process 5.3 Bio-Remediation 5.4 Bio-Sensor 5.5 Genetic Engineering 5.6 Microbial Diversity 5.7 Microbiology / Diagnostics 5.8 Pollution Management 5.9 Sterilization Process 5.10 Waste Management 5.11 Waste Water Treatment 5.12 Bioremediation  Sector - MARINE BIOTECHNOLOGY Sub Sector	1-2 3 4-16 17-21 22-24 25-28 29 30-47 48 49-53 54 55
5.2 Bio-Process 5.3 Bio-Remediation 5.4 Bio-Sensor 5.5 Genetic Engineering 5.6 Microbial Diversity 5.7 Microbiology / Diagnostics 5.8 Pollution Management 5.9 Sterilization Process 5.10 Waste Management 5.11 Waste Water Treatment 5.12 Bioremediation  Sector - MARINE BIOTECHNOLOGY Sub Sector 5.13 Aquaculture	1-2 3 4-16 17-21 22-24 25-28 29 30-47 48 49-53 54 55
5.2 Bio-Process 5.3 Bio-Remediation 5.4 Bio-Sensor 5.5 Genetic Engineering 5.6 Microbial Diversity 5.7 Microbiology / Diagnostics 5.8 Pollution Management 5.9 Sterilization Process 5.10 Waste Management 5.11 Waste Water Treatment 5.12 Bioremediation  Sector - MARINE BIOTECHNOLOGY Sub Sector 5.13 Aquaculture 5.14 Diagnostics	1-2 3 4-16 17-21 22-24 25-28 29 30-47 48 49-53 54 55
5.2 Bio-Process 5.3 Bio-Remediation 5.4 Bio-Sensor 5.5 Genetic Engineering 5.6 Microbial Diversity 5.7 Microbiology / Diagnostics 5.8 Pollution Management 5.9 Sterilization Process 5.10 Waste Management 5.11 Waste Water Treatment 5.12 Bioremediation  Sector - MARINE BIOTECHNOLOGY Sub Sector 5.13 Aquaculture	1-2 3 4-16 17-21 22-24 25-28 29 30-47 48 49-53 54 55
5.2 Bio-Process 5.3 Bio-Remediation 5.4 Bio-Sensor 5.5 Genetic Engineering 5.6 Microbial Diversity 5.7 Microbiology / Diagnostics 5.8 Pollution Management 5.9 Sterilization Process 5.10 Waste Management 5.11 Waste Water Treatment 5.12 Bioremediation  Sector - MARINE BIOTECHNOLOGY Sub Sector 5.13 Aquaculture 5.14 Diagnostics	1-2 3 4-16 17-21 22-24 25-28 29 30-47 48 49-53 54 55
5.2 Bio-Process 5.3 Bio-Remediation 5.4 Bio-Sensor 5.5 Genetic Engineering 5.6 Microbial Diversity 5.7 Microbiology / Diagnostics 5.8 Pollution Management 5.9 Sterilization Process 5.10 Waste Management 5.11 Waste Water Treatment 5.12 Bioremediation  Sector - MARINE BIOTECHNOLOGY Sub Sector 5.13 Aquaculture 5.14 Diagnostics 5.15 Nutrition	1-2 3 4-16 17-21 22-24 25-28 29 30-47 48 49-53 54 55
5.2 Bio-Process 5.3 Bio-Remediation 5.4 Bio-Sensor 5.5 Genetic Engineering 5.6 Microbial Diversity 5.7 Microbiology / Diagnostics 5.8 Pollution Management 5.9 Sterilization Process 5.10 Waste Management 5.11 Waste Water Treatment 5.12 Bioremediation  Sector - MARINE BIOTECHNOLOGY Sub Sector 5.13 Aquaculture 5.14 Diagnostics 5.15 Nutrition 5.16 Vaccines	1-2 3 4-16 17-21 22-24 25-28 29 30-47 48 49-53 54 55

CONTENTS				
	VOLUME - III PHARMACEUTIC			
Sr. No.		Name of Technology	Page No.	
150		Transgenic mice that over express calsequestrin	1	
151	The state of the s	Novel gene and protein involved in glycogen metabolism for use in metabolic (diabetes) and	2	
750	The state of the s	cardiac diseases	2-2	
152	Di Li	Novel candida albicans strain useful for anti-fungal drug screening	3	
153		Annonaceous acetogenin	4	
154 155		Anti-clotting enzyme Development of a novel drug delivery system for biofilm associated infections	6-7	
156		Pattern recognition of whole cell mass spectra	8	
157	biodilalytical ilistrumentation	Equipment, kit and method for microbiological diagnosis	9	
158	Bioanalytical technique	Filtration of red blood cells	10	
159		Versatile novel biocatalysts for pharma synthon production	11-12	
	production			
160	Biomedical application	Fullerenated proteins for biomedical applications	13	
161	Bio-medical instrumentation	Cliniporator™	14	
162		A novel multiplex high accuracy automated DNA sequencer with high throughput of 500 kilo	15	
447		bases per day		
163		Remalog X-ray	16	
164		Percutaneous stent-graft and method for delivery	17	
165		A novel, minimally invasive device for treating vulnerable plaque	18	
166		Cannula for pressure mediated drug delivery	19	
167		Novel method to stimulate bone growth	20-21	
168		Nucleofluor-development of a fluorescent analyzer for the rapid detection of infectious pathogens	22	
169		NMR/MRI magnet for in vivo monitoring of tissue	23	
170		OSCAR™: high yielding protein expression system	24	
171		Intra-urethral device for incontinence	25	
172		Percutaneous device technologies	26	
173		Natural and synthetic materials for use in medical applications	27	
174		A method for operating a laser scanning confocal microscope system and a system thereof	28	
175	The second secon	Optimized orthogonal gradient technique for fast quantitative diffusion MRI on a clinical scanner	29	
176		Intermolecular multiple quantum coherence mr imaging in humans	30	
177		Endoscopic intubations system	31	
178		Apparatus and method for registration of images to physical space using a weighted	32	
0 -		combination of points and surfaces	10,500	
179		Photodynamic therapy with spatially resolved dual spectroscopic monitoring and related system	33	
180	Bio-medical instrumentation/	Real-time PCR for analysis of gene/transcript copy numbers	34	
	molecular diagnostics			
181		A method and system for analyzing an electrocardiographic signal	35	
182	Cell-line study	Serum free cell culture medium	36	
183		A cell line for use in screening pharmacologic agents capable of activating/attentuaing	37	
104	therapeutics	hypoxic activated gene transcription	20	
184	Clinical trials Clinical trials & therapeutics	Method for eliminating wild-type contamination during recombinant viral vector production Clinical immunogene therapy trial to treat renal cell carcinoma patients.	38	
186	Clinical trials a therapeutics  Clinical trials management	Predictive markers and therapeutic targets for drug resistant ovarian cancer	40	
187	Cillical trials management	Implantable biotelemetry system for preterm labor and fetal monitoring	41	
188		Elucidation of a novel breast cancer biomarker and drug target: a novel chloride channel	42	
100		protein, Mat-8		
189		Isolator vascular and endovascular devices — novel bifurcated graft designs for the treatment of abdominal aortic aneurysms (AAAS)	43-44	
190	Clinical trials management/	Method and device for administering medication and placebo (a partial schedule of	45	
No. of Street, or other Persons and Street, o	drug delivery system	pharmacologic reinforcment)		
191	Compound synthesis & screening	Powerful research tool for screening and testing of cholesterol reducing compounds	46	
192	Cytotoxicity	In vitro drug safety testing & new approach technologies	47	
193	Diagnostic & therapeutics	Identification and uses of a DNA digesting enzyme potentially involved in the pathway of	48	
104	Diagnostics	apoptosis and cell death and useful in conditions such as cystic fibrosis	40	
194	Diagnostics	Large scale manufacture of mAb in protein free media	49	

AND THE PERSON NAMED IN	VOLUME THE DUADANCE THE	CALC AND LIFALTHCADE	
Sr. No.	VOLUME – III PHARMACEUTIC Sub-Sector	CALS AND HEALTHCARE  Name of Technology	Dage Ne
Sr. No.	Sub-Sector	Diagnostic tests and means (e.g. labeling kits; monoclonal antibodies; micro array,	Page No.
193		biosensor, and multiplex PCR formats) for the identification of bacterial pathogens	30
		causing pneumonia.	
196		Test kits, antibody/DNA, database, training, patent (brand name)	51
197		Development of medical X-ray digital system	52
198		Measurement of immunosuppressant in patients	53
199	***************************************	Gene therapy target for invasive breast cancer	54-55
200		Diagnostic enzyme reagent kits	56
201		Method for identification of abasic sites in DNA molecules	57-58
202		Diagnostic methods for early cancer detection	59-60
203		HIV-1 infection detection assay for seroconvert HIV-1 vaccine recipients	61
204		Marker for human breast cancer	62
205		Method to detect plant and animal diseases	63
206		Method to improve pathogen detection in poultry	64
207		Molecular determines of the glutamate binding sites	65
208		Novel immunodiagnostics for the detection of Aspergillus infection	66
209		NuNylont: novel nylon technology for high-quality, high-density gene spotting	67
210	Service Property	Production of human disease-specific oligonucleotide micro arrays, and transcription	68-69
		profiling of infectious and inflammatory disease	
211		The development of a high throughput in vitro screening system for detection of endocrine	70-71
	。 一起,可以 一定 一定 一定 一定 一定 一定 一定 一定 一定 一定	disruptors	
212	<b>主动性的 医多种原产的全种原则</b>	Fertility test strip ("safety period" contraception test strip)	72
213		A reliable, non-radioactive method for monitoring accumulation of cholesterol inside	73
		mammalian cells after loading with low density lipoprotein (LDL)	
214	•••••	Composition and methods for enhancing and detecting prion protein	74
215	***************************************	Overview of tissue targeting peptides technology	75
216		In vitro assay to determine the cross-species tissue-binding properties of peptide ligands	76
217		Immunodiagnostics for emerging animal and human parasitic diseases; neosporosis,	77-78
010		toxoplasmosis and fasciolosis	70
218		Improved method for detecting campylobacter in meat	79
219		Inexpensive method for diagnosing tuberculosis infection in a variety of animals	80
220		Monoclonal antibody-based methodologies for the detection and quantification of the HIV-1	81
221		accessory protein vpr in biological samples  New technology to help diagnose tuberculosis in livestock	82
222		Nucleotide sequences for the detection of salmonella	83
223		Method of monitoring exposure to bowman-birk inhibitor (BBI) using monoclonal antibodies	84
223		against bowman birk inhibitor metabolites	04
224		Detection of tumor hypoxia with chemical probes	85
225		Parkinson's disease transgenic mouse model	86
226		Myotonic dystrophy mouse model	87
227		Dioxin responsive lacz mouse model	88
228		Multiplex real-time quantitative RT-PCR	89
229	Diagnostics & monitoring	Monoclonal antibodies for assessing avian immunity to specific diseases	90
230	Diagnostics & predictive	Method for analysis of gene expression profiles to build classifiers and isolate class	91
	J. S. P. Galouro	distinctors	
231	Diagnostics & therapeutics	Discovery BASE screening workflow for target protein identification	92
232		Bioactive peptides – fluorescent-analogues for rapid binding and function screening	93
233		Demonstration of the superior sensitivity of lung densitometry on multi-slice CT images for	94-95
		the assessment of progression of emphysema as compared to conventional lung	
		function tests in a multi-centre study	
234		Use of a human skin explant model for the testing of novel cell lines, drugs etc. in the	96
		modulation of alloreactivity. Cell line and DNA bank for genetic assessment in	
		transplantation	
235		Dual use gene therapy target for treating type I diabetes or as a chemo sensitivity marker	97-98
236		Single lipid nanoparticle	99
237		Typhirapid (rapid diagnosis test of acute typhoid fever)	100
238		Methods of diagnosing, prognosticating and treating collagenase-1 (matrix	101
000	***************************************	metalloproteinase-1) related diseases	100
239		Interaction between androgen receptors and other nuclear receptors	102

	VOLUME – III PHARMACEUTIC		
Sr. No.		Name of Technology	Page No.
240		Biologically active single chain human estrogen receptor variants	103
241		The nogo receptor genes encode a novel family of sialic acid-binding lectins implicated in axonal inhibition	104
242		Apigenin: a potential new anti-plaque/anti-caries agent	105
243		In vitro method for screening for drugs that inhibit production or degradation of human A4- amyloid	106
244		Carotid patch and filter for single view dental panoramic radiographs	107
245		Identification and uses of a peptide potentially involved in the pathogenesis of type i diabetes mellitus	108-109
246	Diagnostics & treatment	Chondrocyte proteins	110
247	Diagnostics & vaccines	Proteins for immunizing animals against cryptosporidiosis	111
248		Passive intranasal monoclonal antibody prophylaxis against pneumocystis carinii pneumonia	112
249	Diagnostics / mabs	Monoclonal antibodies and antibody cocktail for detection of prion protein as an indication of transmissible spongiform encephalopathies	113
250	Diagnostics, therapeutics, immunobiology	Three novel human peptidoglycan-recognition proteins	114-115
251	Diagnostics/ bioassays	Development and validation of a DNA-chip technology for the assessment of the bacteriological quality of bathing and drinking water	116
252		A dedicated wide-bore ultra-high-field MAS NMR spectrometer, probes, accessories, software and sample preparation methods for biological mas NMR and imaging research	117-118
253		NMR structures of membrane proteins, complexes and lipid assemblies; a dedicated wide- bore ultra high field MAS NMR spectrometer for biological research	119-120
254	Drug discovery	Discovery of a new class of antitumor agents	121
255		Tissue engineering technologies on drug delivery/ targeting	122
256		Mesangial cell lines as models for the study and treatment of diabetic tissue complications	123
257		Use of monobodies for target validation in drug discovery	124
258	Functional genomics	Genetic epidemiological study	125
259	Gene amplification	Genetic polymorphisms which are associated with autism spectrum disorders	126
260	Gene expression study	A novel model with externally controlled gene switch	127
261	Gene therapy	Human beta-hexosaminidase therapeutic transgene (β-Hex) for gene therapy of tay sachs and sandhoffs diseases	128
262	Gene transfer & therapeutics	Development of receptors to optimally retarget human t cells to MHC-restricted tumor or viral antigens.	129
263		Development of a highly efficient retroviral vector and gene delivery system to transducer primary human T cells under GMP conditions.	130
264	Genetic diversity exploitation	Genotyping of parasites in breakthrough cases in RTS, S/AS02 and control groups, in the gambia, 1999 and in the mozambique phase II efficacy study, 2003-2004.	131
265	Genome analysis	Single-site amplification (SSA): method for accelerated development of nucleic acid markers	132
266	Genomics	Development of functional genomic approaches to cancer genetics	133
267	Immunotherapeutic	Chimeric NK receptors as a basis for immunotherapy of cancer	134
268		Novel immunotherapy for ovarian cancer	135-136
269	Mabs	Novel monoclonal antibodies to porcine lymphocytes	137
270		Monoclonal antibody of APE/Ref-1	138
271	Media	Improved strategy for the design of chemically defined media for the production of biopharmaceuticals. Establ ishement of cell banks under protein-free cryopreservation conditions	139
272	Molecular biology	Streptomyces	140-141
273	Molecular biomarkers &	Circulating osteoclast precursors as markers of bone resorption in inflammatory arthritis	140-141
274	therapeutics Molecular diagnostics	MELVIR- diagnosis of melanoma	143
275		Simple method for protease screening	144-145
276		Monoclonal antibody directed to an antigen derived from human ovarian tumors and a radioimmunoassay using the antibody	146
277	Molecular diagnostics & therapeutics	Peptides mimicking vibrio cholerae O139 capsular polysaccharide and their use to elicit protective immune response	147-148
278		Assays to screen for inhibitors of FtsA interactions, a protein vital for bacterial proliferation.	149
279		HIV neutralization by structure-based enhancements of CD4-molecular mimicry	150
***************************************			

		CONTENT	
	VOLUME – III PHARMACEUTIO		
Sr. No.	Sub-Sector	Name of Technology	Page No.
280	Molecular diagnostics & vaccines	Immunogenic conjugates of gram-negative bacterial auto inducer molecules	151
281	Molecular markers	Antibody multilineage marker for surface of apoptotic cells	152-153
282	Molecular targets & diagnostics	Groundbreaking CpG-related targets and diagnostics	154
283		Muscle-specific targeting peptides	155
284	Molecular therapeutics	Delineation of a novel pathway that regulates human CD154 (CD40 ligand) gene expression	156-157
285		Treating/preventing heart failure via inhibition of mast cell degranulation	158
286		Human glandular kallikrein (hK2)-specific monoclonal antibodies that either enhance or inhibit the enzymatic activity of hK2	159
287		Suppression of androgen receptor tran activation through new signaling pathways	160
288		Glucocorticoid-regulated VEGF expression via plasmid-bases delivery	161
289		E7 regulation of p21Cip1 through AKT	162
290	Patient management system	Method and system for monitoring and treating a patient	163
291	Pharmacogenetics/ therapeutics	Discovery and characterization of the Pioneer Round of mRNA translation	164
292	Pre-clinical testing	Polymeric intraocular lens implants	165
293	Target therapeutics	A novel pharmacological pathway which destabilizes lysosomes and targets oncogenic or other aberrant proteins for destruction	166
294	Targeted molecular therapeutics	Compositions and methods for inhibiting the synthesis or expression of MMP-1 or treating, preventing or managing cancer	167
295	Therapeutic markers/ mabs	Antibody marker for apoptotic myeloid cells	168-169
296	Therapeutics	Antibiotic biosynthesis enzymes	170
297		Drug development by genome based technologies	171
298		ET-743 (yon delis) a new chemical entity with potential in cancer treatment	172
299		Non-ribosomal peptide synthesis	173
300		Bruker method for spiral and radial MRI, and animal MRI compatible ventilator for small animals	174
301		Anti-bacterial (MRSA) drug series, (the XF drugs).	175
302		Novel anti bacterial drug candidates based on toxin-antitoxin modules	176-177
303		High and stable recombinant virus production by recombinase mediated targeting of hot- spot chromosomal integration sites	178
304		Bioartificial liver, immortalised human liver cell line	179
305		Novel molecule for treatment of transplant rejection	180-181
306		Preparation of phenylalanine-free protein and production of the protein through recombinant methods for oral administration to individuals with phenylketonuria	182-183
307		Therapeutic applications for a novel synergistic combination of myeloid progenitor cell regulators	184
308		Novel enantioselective catalysts useful in the synthesis of á-amino acid derivatives	185
309		Polypeptides useful in the prevention of dental caries	186-187
310	The state of the Artist	Novel pharmacotherapeutic composition & process for treatment of central nervous system disorders	188-189
311		Lactase-based digestive supplement	190
312		Lumbrokinase	191
313		Methods for tissue specific and inducible inhibition of gene expression	192
314		New immuno-regulating drug	193
315		New plasma substitute	194
316		Novel method of drug delivery through the blood-brain barrier	195-196
317		Novel strategy in antithrombotic therapy: inhibition of the initial phase of thrombogenesis	197
318		Flexi bone: osteo-mimetic composites, IB-2104	198-199
319 320		Micro gels for vaccine and cytoplasmic drug delivery  Peptides for the controllable promotion or inhibition of bone growth, IB-2080	200-201 202-203
321		Dressing with long therapeutic effect	202-203
322		Isolation of novel anti-inflammatory agents derived from the symbiotic dinoflagellate,	205
		pseudopterogorgia elisabethae	
323		Polysaccharide hydrogel as an organic carrier for human joints	206
324	1.	Radiation therapy for chronic lymphocytic leukemia  Compositions and methods of treating, reducing, and preventing cardiovascular diseases	207
325		and disorders with polymethoxyflavones	200

	VOLUME – III PHARMACEUTIO	CALS AND HEALTHCARE	
Sr. No.	Sub-Sector	Name of Technology	Page No.
326		New molecules from starch	209
327		New source and method for producing anti-cancer drugs	210
328		Reversible gels for delivery of therapeutics	211
329		Double-stranded RNA for telomerase inhibition	212
330		Methods, articles and compositions for the pharmacologic inhibition of bone resorption with phosphodiesterase inhibitors	213
331		Tumor suppressing nature of Thy-1 and the induction of its expression	214
332		Immortalized embryonic mesencephalic glial cells	215
333	Therapeutics & targets	A novel method to enhance the activity of routinely used anticancer agents	216
334	Therapeutics & vaccines	CIM® monolithic chromatographic supports — enabling technology for analysis and purification of novel biotherapeuticals	217
335		Identification and uses of an immunoadjuvant-enhanced, immunotargeted vaccine therapy	218
336		Rapid production of autologous tumor vaccines	219
337	Therapeutics / drug development	Method for conditional expression of RNA from an RNA polymerase III promoter	220
338	Tissue engineering	A novel scaffold for tissue engineering applications \	221-222
339		Cell technologies and bioreactors	223
340		Orthopaedic and dental tissue engineering	224
341		Soft tissue applications	225
342		Anchorage means for isoelastic implants	226
343		Soft tissue implant with micron-scale surface texture to optimize anchorage	227
344	Vaccines	Improved production process for the manufacturing of vaccines	228-229
345		Phage display of peptide/MHC complexes	230
346		New streptococcal vaccine	231

GSBTM Editorial Team: Technology Scroll

Chief Editor: Akshay Saxena, IFS

Executive Editor: Snehal Bagatharia, Ph.D.

Editorial Assistants Taru Nagori Jigar M. Shah Rakesh kumawat Rohini P. Shah Bhavesh Nayak

Graphics & Design: Samalson Designs

**GSBTM 2006** 



#### **GUJARAT STATE BIOTECHNOLOGY MISSION**

Department of Science & Technology, Government of Gujarat Block-11, 9th Floor, Udyog Bhavan, Gandhinagar-382017 Phone: 91-79-232 52196,97 Fax: 91-79-232 52195 web site: http://btm.gujarat.gov.in E-mail:info-btm@gujarat.gov.in